NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synergy Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range$0.01MA: $0.02▼$0.0352-Week Range N/AVolumeN/AAverage Volume6.08 million shsMarket Capitalization$7.44 millionP/E RatioN/ADividend YieldN/ABeta4.94 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGYP Previous Symbol CUSIP87163930 CIK1347613 Webhttp://www.synergypharma.com/ Phone212-297-0020Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$16.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.02) Net Income$-224,330,000.00 Net Margins-332.11% Return on EquityN/A Return on Assets-118.14%Miscellaneous EmployeesN/A Outstanding Shares248,040,000Market Cap$7.44 million Next Earnings DateN/A OptionableOptionable Receive SGYP News and Ratings via Email Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter. Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions What is Synergy Pharmaceuticals' stock symbol? Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP." How were Synergy Pharmaceuticals' earnings last quarter? Synergy Pharmaceuticals Inc (NASDAQ:SGYP) posted its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million. View Synergy Pharmaceuticals' Earnings History. Has Synergy Pharmaceuticals been receiving favorable news coverage? Press coverage about SGYP stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Synergy Pharmaceuticals earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the next few days. View News Stories for Synergy Pharmaceuticals. Who are some of Synergy Pharmaceuticals' key competitors? Some companies that are related to Synergy Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Synergy Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), ACADIA Pharmaceuticals (ACAD), Immunomedics (IMMU), Cara Therapeutics (CARA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Opko Health (OPK), Verastem (VSTM) and NVIDIA (NVDA). Who are Synergy Pharmaceuticals' key executives? Synergy Pharmaceuticals' management team includes the folowing people: Mr. Troy Hamilton Pharm.D., CEO & Director (Age 47)Mr. Gary G. Gemignani, Exec. VP & CFO (Age 54)Gem Gokmen Hopkins, VP of Investor Relations and Corp. CommunicationsMs. Pamela Cebulski, Sr. VP of MarketingMs. Marianne Jackson, Sr. VP of Sales & Market Access How big of a company is Synergy Pharmaceuticals? Synergy Pharmaceuticals has a market capitalization of $0.00 and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. View Additional Information About Synergy Pharmaceuticals. What is Synergy Pharmaceuticals' official website? The official website for Synergy Pharmaceuticals is http://www.synergypharma.com/. How can I contact Synergy Pharmaceuticals? Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected] MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 728 (Vote Outperform)Underperform Votes: 478 (Vote Underperform)Total Votes: 1,206MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: Treasury Bonds
